BIIB054, a drug candidate that was discovered by Neurimmune and acquired by Biogen in 2010, has reached a significant milestone of initiation of a Phase 1 clinical trial of BIIB054. BIIB054 is a human recombinant monoclonal antibody targeting alpha-synuclein, a target that is believed to play a central role in Parkinson's disease.
BIIB054 reached significant milestone
02.07.2015
